ETFMG Treatments, Testing and Advancements ETF (GERM)

BATS BZX Real-Time Price
As of 2:36pm ET
 +0.59 / +1.62%
Today’s Change
Today|||52-Week Range

Investment Objective

The investment seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of the Prime Treatments, Testing and Advancements Index. The index tracks the performance of U.S.-listed equity securities or depositary receipts of companies that (i) perform research, development, and commercialization of treatments or vaccines for infectious diseases or (ii) engage in the research, development, manufacturing, and provision of biological tests for patients. The fund invests at least 80% of its total assets in the component securities of the index. The fund is non-diversified.

No recent news for ETFMG Treatments, Testing and Advancements ETF.


1 month-0.23% 3 years--
3 months+1.68% 5 years--
1 year-- Since inception+46.43%
Data through 04/15/2021

Quote Details

Previous close$36.40
Open day’s range36.55 – 36.99
Net asset value (NAV)36.31 (04/14/2021)
Daily volume18,815
Average volume (3 months)31,707
Data as of 2:36pm ET, 04/16/2021

Peer Comparisonvs. Health ETFs

Performance 5-yr return--+15.28%
Expense Gross exp ratio0.68%1.02%
Risk 5 year sharpe ratio--0.80
Net assets$56.7M$2.3B
Average market cap$10.7B$31.0B
Average P/E--28.0
Dividend / Share--0.29%


No competitors data available.


Top 5 Sectors
Portfolio weighting
Business service --
Consumer goods --
Consumer service --
Energy --
Financial service --
Top 10 Holdings
Portfolio weighting
BNTX BioNTech SE6.47%
LH Laboratory Corporation of America Holdings6.11%
ALNY Alnylam Pharmaceuticals Inc5.79%
BIO Bio Rad Laboratories Inc5.72%
MRNA Moderna Inc5.58%
NVAX Novavax Inc4.30%
ABCL Abcellera Biologics Inc4.26%
-- 4.22%
DGX Quest Diagnostics Inc4.10%
ZLAB Zai Lab Ltd3.76%